GlassScriptPhysician profile
Angela Olomon
NPI 1487618062
$4,209.31
in general payments reported to CMS, 2019-2025
39 companies · $30.25 in 2025
The $30.25 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $539 · 2021: $930 · 2022: $1,233 · 2023: $556 · 2024: $13.96 · 2025: $30.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $474.03 | 2019-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $431.91 | 2019-2023 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $357.50 | 2019-2022 | |
| Abbvie INC. | $336.79 | 2021-2025 | |
| Alkermes, INC. | $260.87 | 2019-2023 | Aristada, Lybalvi |
| Lundbeck LLC | $241.41 | 2019-2023 | Rexulti |
| Allergan, INC. | $230.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $167.54 | 2019-2023 | Xarelto |
| Sunovion Pharmaceuticals INC. | $152.28 | 2019-2022 | |
| Novo Nordisk INC | $140.01 | 2020-2025 | Ozempic, Rybelsus |
| Indivior INC. | $135.55 | 2021-2023 | Perseris |
| Mallinckrodt Hospital Products INC. | $129.69 | 2023 | Acthar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.84 | 2020-2022 | |
| Glaxosmithkline, LLC. | $110.68 | 2022-2023 | Nucala |
| Vanda Pharmaceuticals INC. | $89.77 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Olomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.